KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Assets Average (2016 - 2025)

Historic Assets Average for Nektar Therapeutics (NKTR) over the last 15 years, with Q3 2025 value amounting to $254.4 million.

  • Nektar Therapeutics' Assets Average fell 2186.69% to $254.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $254.4 million, marking a year-over-year decrease of 2186.69%. This contributed to the annual value of $350.9 million for FY2024, which is 3668.93% down from last year.
  • Latest data reveals that Nektar Therapeutics reported Assets Average of $254.4 million as of Q3 2025, which was down 2186.69% from $231.9 million recorded in Q2 2025.
  • Nektar Therapeutics' Assets Average's 5-year high stood at $1.5 billion during Q1 2021, with a 5-year trough of $231.9 million in Q2 2025.
  • Over the past 5 years, Nektar Therapeutics' median Assets Average value was $528.0 million (recorded in 2023), while the average stood at $696.4 million.
  • In the last 5 years, Nektar Therapeutics' Assets Average plummeted by 1465.9% in 2021 and then crashed by 4401.04% in 2023.
  • Nektar Therapeutics' Assets Average (Quarter) stood at $1.2 billion in 2021, then tumbled by 37.71% to $745.8 million in 2022, then plummeted by 43.67% to $420.1 million in 2023, then dropped by 27.19% to $305.9 million in 2024, then decreased by 16.82% to $254.4 million in 2025.
  • Its Assets Average was $254.4 million in Q3 2025, compared to $231.9 million in Q2 2025 and $280.0 million in Q1 2025.